Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Teoxane proposal to acquire Revance Therapeutics
We are advising Teoxane on the proposed acquisition
Banco Santander México $700 million senior notes offering
We advised Banco Santander México on the investment-grade offering
Amer Sports $1.05 billion follow-on offering
We advised Amer Sports on its SEC-registered offering
Aker BP $1.5 billion notes offering
The notes are due 2034 and 2054
NatWest Group $750 million contingent convertible Additional Tier 1 notes
We advised NatWest Group on the SEC-registered offering
Banco Santander renewal of $25 billion U.S. commercial paper program
We advised Banco Santander on its program renewal
Boparan £470 million refinancing
We advised on a high-yield notes offering, tender offer and credit facility refinancing
Gates Industrial $226 million secondary offering
The offering involved approximately 11.6 million ordinary shares
ATSG $3.1 billion acquisition by Stonepeak
We are advising Air Transport Services Group on its going-private transaction